BSX
A haircut, not a breakup
Baird took a little scissors to Boston Scientific’s price target, dropping it to $86 from $95, but it kept the stock at Outperform. Translation: the firm still thinks BSX is a decent horse to bet on, it just shaved off some of the runway.
Why that matters
Analyst notes like this can move a stock around the edges, especially when they come with a target cut. But the bigger signal is the rating: Baird didn’t throw Boston Scientific into the “sell it and never look back” bucket. It’s more of a subtle recalibration than a full-on mood swing.
The Street is still reasonably upbeat
FactSet says Boston Scientific still has:
- an average Buy rating
- a mean price target of $97.39
So Baird’s new $86 target is lower than the Street’s average, but not exactly a doomsday forecast. Think of it like your friend saying, “I’m still in for dinner, I’m just ordering the cheaper wine.”
Big picture
For BSX investors, the takeaway is simple: the bullish case is still intact, but some analysts are getting a touch more conservative on how far the stock can run from here. That’s not a thesis-breaker — just a reminder that even the optimists are doing a little math.